Evidence map›Paper›PMID 38374135›Full record

ArticleScientific reports2024

Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study.

Sang Heon Suh, Tae Ryom Oh, Hong Sang Choi, Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Kook-Hwan Oh, Kyu-Beck Lee, Jong Cheol Jeong, Ji Yong Jung and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sang Heon SuhDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.ORCID http://orcid.org/0000-0003-3076-3466
Tae Ryom OhDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.ORCID http://orcid.org/0000-0002-3713-0939
Hong Sang ChoiDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.ORCID http://orcid.org/0000-0001-8191-4071
Chang Seong KimDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.ORCID http://orcid.org/0000-0001-8753-7641
Eun Hui BaeDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.ORCID http://orcid.org/0000-0003-1727-2822
Seong Kwon MaDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.ORCID http://orcid.org/0000-0002-5758-8189
Kook-Hwan OhDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.ORCID http://orcid.org/0000-0001-9525-2179
Kyu-Beck LeeDivision of Nephrology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID http://orcid.org/0000-0002-3904-5404
Jong Cheol JeongDivision of Nephrology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.ORCID http://orcid.org/0000-0003-0301-7644
Ji Yong JungDivision of Nephrology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.ORCID http://orcid.org/0000-0003-1271-8012
Soo Wan KimDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea. skimw@chonnam.ac.kr.ORCID http://orcid.org/0000-0002-3540-9004
Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators

Funding

the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) RS-2023-00217317the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) RS-2023-00278258the Research Program funded by the Korea Disease Control and Prevention Agency 2011E3300300the Research Program funded by the Korea Disease Control and Prevention Agency 2012E3301100the Research Program funded by the Korea Disease Control and Prevention Agency 2013E3301600the Research Program funded by the Korea Disease Control and Prevention Agency 2013E3301601the Research Program funded by the Korea Disease Control and Prevention Agency 2013E3301602the Research Program funded by the Korea Disease Control and Prevention Agency 2016E3300200the Research Program funded by the Korea Disease Control and Prevention Agency 2016E3300201the Research Program funded by the Korea Disease Control and Prevention Agency 2016E3300202the Research Program funded by the Korea Disease Control and Prevention Agency 2019E320100the Research Program funded by the Korea Disease Control and Prevention Agency 2019E320101the Research Program funded by the Korea Disease Control and Prevention Agency 2019E320102the Research Program funded by the Korea Disease Control and Prevention Agency 2022-11-007
6 · The paper itself

Abstract

While the relationship between circulating osteoprotegerin (OPG) and cardiovascular events is well-established in the general population, its association with cardiovascular risks in chronic kidney disease (CKD) patients remains less robust. This study hypothesized that elevated circulating OPG levels might be associated with an increased risk of major adverse cardiac events (MACE) in CKD patients, a total of 2,109 patients with CKD stages 1 through pre-dialysis 5 from the KNOW-CKD cohort were categorized into quartiles based on serum OPG levels. The primary outcome of the study was 3-point MACE, defined as a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiac death. The median follow-up duration was 7.9 years. The cumulative incidence of 3-point MACE significantly varied across serum OPG levels in Kaplan-Meier curve analysis (P < 0.001, log-rank test), with the highest incidence observed in the 4th quartile. Cox regression analysis indicated that, relative to the 1st quartile, the risk of 3-point MACE was significantly higher in the 3rd (adjusted hazard ratio 2.901, 95% confidence interval 1.009 to 8.341) and the 4th quartiles (adjusted hazard ratio 4.347, 95% confidence interval 1.410 to 13.395). In conclusion, elevated circulating OPG levels are associated with adverse cardiovascular outcomes in pre-dialysis CKD patients.

Indexed as

Cardiovascular DiseasesMyocardial InfarctionRenal Insufficiency, ChronicCardiovascular SystemDialysisHumansOsteoprotegerinRisk FactorsOsteoprotegerinBiomarkerChronic kidney diseaseMajor adverse cardiac eventOsteoprotegerin

Identifiers

PMID38374135
PMCPMC10876961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.